Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
In patients at very high cardiovascular risk, PCSK9i and inclisiran therapies are associated with significantly lower visit-to-visit LDL-C variability compared to standard statin-based regimens. These findings support the importance of not only achieving LDL-C targets but also maintaining lipid stability over time, which may contribute to improved cardiovascular outcomes.
Authors
- Paolo Calabrò (ORCID: https://orcid.org/0000-0002-5018-830X)
- Vincenzo De Sio (ORCID: https://orcid.org/0009-0001-1609-4684)
- Domenico Panico
- Stefano Carugo
- Andrea Zito
- Massimiliano Ruscica (ORCID: https://orcid.org/0000-0002-0195-7061)
- Michele Golino (ORCID: https://orcid.org/0000-0003-0141-0127)
- Arturo Cesaro (ORCID: https://orcid.org/0000-0003-4435-1235)
- Felice Gragnano (ORCID: https://orcid.org/0000-0002-6943-278X)
- Francesco Scialla
- Alberto Corsini (ORCID: https://orcid.org/0000-0002-9912-9482)
- Vincenzo Acerbo
- G. Argenziano
- Maria Grazia Monaco (ORCID: https://orcid.org/0009-0004-2703-4232)
- Gennaro Porcelli
- Demetrio Iaria
Institutions
- Virginia Commonwealth University (US)
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- I.R.C.C.S. Oasi Maria SS (IT)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1016/j.jacl.2025.10.066
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01